Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Asia Pacific Prostate Cancer Conference /
Cost constraints affect treatment decision-making in China and Singapore - expert discussion

1st - 2nd Mar 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.03.14
Views: 2697
Rating:

Prof Kurt Miller, Dr Li-qun Zhou and Dr Ravindran Kanesvaran

Speaking to ecancer from the Academy for Cancer Education (ACE) 3rd Asia Pacific Prostate Cancer Conference (APPCC) in Shanghai, Prof Kurt Miller from Benjamin Franklin Medical Centre, Berlin, Germany, interviews Dr Li-qun Zhou from Peking University First Hospital, Bejing, China, and Dr Ravindran Kanesvaran from the National Cancer Centre Singapore, Singapore.

The experts first comment on which drugs are available in their respective countries for CRPC and how patients are routinely treated. This gives viewers an interesting perspective on differences and similarities around the globe.

They comment on the use of chemotherapy and agents such as abiraterone (which is not yet available in China), and the balance of efficacy, toxicity and cost. They focus on issues surrounding cost, with patients needing to pay for their own treatments in many countries, and how that affects treatment choice. 

They also discuss sequence of therapy, and the use of radium-223 in their respective countries.

The experts finally discuss which specialists are treating patients with prostate cancer, e.g. urologists vs. oncologists, how often they are reviewed and in which clinical setting they are managed, e.g. in- vs. out-patient therapy, in their respective countries. The value of multi-disciplinary teams in prostate cancer care is also emphasised.

This video is sponsored by an educational grant from Janssen Asia Pacific, pharmaceutical companies of Johnson & Johnson

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation